These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. [Clinical, hematologic and developmental characteristics of myelodysplastic syndromes. Study of a group of patients with a long-term follow-up]. Di Giovanni S; Giallonardo P; Costa MP; Carducci P Recenti Prog Med; 1987 Feb; 78(2):63-8. PubMed ID: 3473582 [No Abstract] [Full Text] [Related]
10. Donor lymphocyte infusions for post-transplant relapse of refractory anemia with excess blasts and monosomy 7. Skinner R; Velangi M; Bown N Pediatr Blood Cancer; 2008 Mar; 50(3):670-2. PubMed ID: 17253642 [TBL] [Abstract][Full Text] [Related]
12. [Successful induction chemotherapy for childhood RAEB-T with VP-16: a case report]. Tanizawa A; Sonomura T; Wakazono Y; Akiyama Y; Kubota M; Mikawa H Rinsho Ketsueki; 1989 Jul; 30(7):1052-7. PubMed ID: 2810790 [TBL] [Abstract][Full Text] [Related]
13. A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. Garcia-Manero G; Faderl S; Giles F; Thomas D; Cortes J; O'Brien S; Davis J; Kantarjian HM; Estey E Haematologica; 2002 Aug; 87(8):804-7. PubMed ID: 12161355 [TBL] [Abstract][Full Text] [Related]
14. Induction of complete remission in a patient with acute myeloid leukemia refractory to high-dose chemotherapy through treatment with 5-azacytidine. Kuendgen A; Gräf T; Zohren F; Hildebrandt B; Hünerlitürkoglu A; Gattermann N; Haas R; Kobbe G Leuk Res; 2007 Mar; 31(3):407-9. PubMed ID: 16890286 [TBL] [Abstract][Full Text] [Related]
16. Differences between refractory anemia with excess blasts in transformation and acute myeloid leukemia. Albitar M; Beran M; O'Brien S; Kantarjian H; Frieriech E; Keating M; Estey E Blood; 2000 Jul; 96(1):372-3. PubMed ID: 10939804 [No Abstract] [Full Text] [Related]
17. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346 [TBL] [Abstract][Full Text] [Related]
18. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213 [TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndrome presenting as cutaneous vasculitis. O'Donnell BF; Williams HC; Carr R Clin Exp Dermatol; 1995 Sep; 20(5):439-42. PubMed ID: 8593729 [TBL] [Abstract][Full Text] [Related]
20. [Successful treatment of refractory anemia with excess of blasts in transformation with cytarabine ocfosfate]. Takeuchi M; Kojima K; Takaba S; Isokawa M; Tanimizu M; Kimura F; Ohmoto E; Harada M Gan To Kagaku Ryoho; 1995 Jan; 22(1):141-4. PubMed ID: 7826071 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]